SCHEMBL5010922

SCHEMBL5010922

O=S(=O)(O)c1ccccc1-c1ccccn1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.52
LMNA P02545 3/20 0.52
P4HTM Q9NXG6 3/20 0.52
CCR1 P32246 2/20 0.52
CCR5 P51681 2/20 0.52
CCR8 P51685 2/20 0.52
CYP1A2 P05177 2/20 0.52
POLB P06746 1/20 0.52
METAP1 P53582 1/20 0.52
BLM P54132 1/20 0.52
HIF1A Q16665 1/20 0.52
DOHH Q9BU89 1/20 0.52
EDNRA P25101 2/20 0.49
TP53 P04637 3/20 0.45
TDP1 Q9NUW8 3/20 0.45
ALOX15 P16050 2/20 0.45
HTT P42858 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
ALDH1A1 P00352 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8641370 0.85 TDP2 (0.46) KDM4ELMNAP4HTMCCR1CCR5
Dipyridyl SCHEMBL27903420 0.82 KDM4E (0.70) KDM4ELMNAP4HTMCCR1CCR5
SCHEMBL1205852 0.81 EDNRA (0.52) KDM4ELMNAP4HTMCCR1CCR5
SCHEMBL28898669 0.81 EDNRA (0.49) KDM4ELMNAP4HTMCCR1CCR5
SCHEMBL1667127 0.81 EDNRA (0.49) KDM4ELMNAP4HTMCCR1CCR5
SCHEMBL29967288 0.81 EDNRA (0.49) KDM4ELMNAP4HTMCCR1CCR5
SCHEMBL27751597 0.81 EDNRA (0.47) KDM4ELMNACYP1A2POLBBLM
SCHEMBL27727298 0.81 EDNRA (0.42) KDM4EPOLBEDNRAALOX15ALDH1A1
SCHEMBL5691577 0.80 KDM4E (0.47) KDM4ELMNAP4HTMCCR1CCR5
SCHEMBL5314142 0.80 KDM4E (0.50) KDM4ELMNAP4HTMCCR1CCR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1697362-B1 CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO SB PHARMCO INC (PR) 2008-03-05 EP disclosed
US-20070293508-A1 Crf Receptor Antagonists and Methods Relating Thereto SB PHARMCO PUERTO RICO INC AND NEUROCRINE BIOSCIENCES, INC. (US) 2007-12-20 US disclosed
EP-1697362-A1 CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO SB Pharmco Puerto Rico Inc. (PR) 2006-09-06 EP disclosed
WO-2005063749-A1 CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO SB PHARMCO PUERTO RICO INC (GB) 2005-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070293508-A1 Crf Receptor Antagonists and Methods Relating Thereto CRHR1, CRHR2, SCTR KDM4E 4530/4885LMNA 3846/4885P4HTM 632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.